June 10th, 2025 | 07:05 CEST
Palantir, NetraMark, Qualcomm – Caution, buy signals!
Artificial intelligence is fundamentally changing the economy. It optimizes processes, reduces costs, and creates new business models. Its use in the healthcare and pharmaceutical sectors is currently developing particularly dynamically. Data-based decisions and personalized medicine are significantly increasing efficiency. According to experts, the global market for AI in healthcare could grow disproportionately in the coming years. Many AI companies are still in the early stages of their development.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
PALANTIR TECHNOLOGIES INC | US69608A1088 , NETRAMARK HOLDINGS INC | CA64119M1059 , QUALCOMM INC. DL-_0001 | US7475251036
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Palantir – A milestone in healthcare
Controversial data specialist Palantir is present in many areas of society. The US company's technology is used in areas such as counterterrorism, law enforcement, and supply chain management in industry.
With its latest joint venture, however, the team led by CEO Alex Karp is setting a milestone for data-driven, scalable, and sustainable healthcare. Palantir Technologies and TeleTracking Technologies have entered into a strategic partnership to fundamentally transform healthcare through AI-powered data platforms. The goal is to provide hospitals and healthcare systems worldwide with actionable insights in near real-time. At the heart of the collaboration is the integration of TeleTracking's "Operations IQ" with Palantir's AI operating systems "Foundry" and "AIP".
The combined solution is designed to optimize staffing processes, speed up decision-making, and make patient care more efficient - without the need for additional physical infrastructure. By leveraging operational command centers, predictive models, and connected data sources, healthcare organizations can dynamically manage resources, staffing, and capacity. At the same time, the burden on medical staff is reduced while outcomes and cost structures are improved.
After a brief correction, Palantir shares are continuing to move toward their all-time high of USD 135.28. The data specialist is receiving tailwinds from the indicators. The relative strength index is at a neutral 56 points, far from the overbought range.
NetraMark – Disruption in the pharmaceutical sector
NetraMark, valued at CAD 114.72 million, could also become a takeover candidate due to its outstanding AI-based technology. NetraMark exemplifies the disruptive potential of artificial intelligence in the healthcare sector. The Canadian company aims to fundamentally transform clinical research with its NetraAI platform. Given that around 90% of all clinical trials fail between drug development and market approval, especially in the cost-intensive Phase 3, NetraMark's data-driven approach is right on trend.
The NetraAI platform combines AI algorithms with modules such as NetraGPT to extract valid patterns even from small amounts of data. This enables early prediction of treatment success, identification of risks, and reduction of study duration by up to 30%. At the same time, dropout rates are significantly reduced, saving time and money. The goal is to dramatically increase the efficiency of clinical trials and thus address a market worth billions.
A significant milestone is the partnership with Worldwide Clinical Trials (WCT), through whose global network NetraAI will be integrated into Phase 2 studies for neurological and oncological therapies. Further collaborations exist with the National Institute of Mental Health and a leading pharmaceutical company.
The potential is already evident in the stock market. After a price increase of over 1,000% between August 2024 and March 2025, the share is currently in a consolidation phase. Insider purchases, most recently by director P.J. Haley, who acquired over 600,000 shares at the end of May, highlight management's confidence in its strategy. NetraMark is aiming for positive EBITDA by the end of the year. If the ambitious growth plans are successfully implemented, the current valuation should have significant upside potential.
Qualcomm – Crucial situation
From a technical perspective, the wireless communications technology specialist, which plays a central role in the global mobile communications ecosystem, particularly in the development and licensing of mobile communications standards such as 3G, LTE, and 5G, is still a long way from where Palantir shares currently stand. Qualcomm's high - currently trading at USD 149.70 - dates back to April last year at USD 230. Nevertheless, the stock could gain upward momentum if the wedge formation is sustainably broken at USD 152.95.
In any case, MACD and RSI are about to generate a buy signal. If the striking horizontal resistance at USD 161.82 is broken, the way would be clear for at least a move into the USD 180 zone.
Qualcomm is pushing ahead with its expansion in the mega-market of AI data centers and has acquired British chip developer Alphawave for around USD 2.4 billion. With this acquisition, the smartphone chip giant aims to reduce its dependence on the mobile communications segment and tap into new growth areas.
Alphawave, which specializes in high-speed connectivity for data centers, will complement Qualcomm's energy-efficient processors. The cash offer is 183 pence per share. After the announcement, Alphawave's share price rose by around 25%.
Data giant Palantir is setting a milestone in healthcare through its collaboration with TeleTracking Technologies. NetraMark aims to revolutionize clinical trials in the pharmaceutical industry with its AI-powered technology. Qualcomm is becoming less dependent on its mobile communications business through its billion-dollar acquisition of Alphawave.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
